Literature DB >> 16023760

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.

Luigi Fiume1, Luigi Bolondi, Corrado Busi, Pasquale Chieco, Felix Kratz, Marcella Lanza, Alessandro Mattioli, Giuseppina Di Stefano.   

Abstract

BACKGROUND/AIMS: The hepatocyte receptor for asialoglycoproteins internalizes galactosyl terminating macromolecules which can be used as hepatotropic drug carriers. Since this receptor is also expressed on the cells of well differentiated human hepatocellular carcinomas (HCCs), we studied whether conjugation of doxorubicin (DOXO) with lactosaminated human albumin (L-HSA) increases the drug efficacy on HCCs induced in rats by diethylnitrosamine (DENA).
METHODS: DENA was given in the drinking water for 8 weeks. One week after the last day of DENA administration, animals were randomly assigned to three groups. Each group was administered with either saline, free or coupled DOXO (1 microg/g). Rats received 4 weekly intravenous injections. One week after the last administration, rats were killed and HCC development was evaluated by counting the tumor nodules on the surface of hepatic lobes.
RESULTS: In rats treated with L-HSA coupled DOXO the number of neoplastic nodules was significantly lower (P < 0.05) than that counted in animals injected with saline or with free DOXO. Coupled DOXO did not decrease body rat weight, which was markedly reduced by the free drug.
CONCLUSIONS: Conjugation with L-HSA increased the antineoplastic efficacy and decreased the systemic toxicity of DOXO administered to rats with HCCs produced by DENA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023760     DOI: 10.1016/j.jhep.2005.02.045

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

Review 1.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405

2.  A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.

Authors:  Ximin Chen; Guipeng Ding; Qihe Gao; Jian Sun; Qianqian Zhang; Lijian Du; Zhenning Qiu; Changjun Wang; Feng Zheng; Bowang Sun; Jian Ni; Zhenqing Feng; Jin Zhu
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

3.  Differences in the properties and mirna expression profiles between side populations from hepatic cancer cells and normal liver cells.

Authors:  Wei-hui Liu; Kai-shan Tao; Nan You; Zheng-cai Liu; Hong-tao Zhang; Ke-feng Dou
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

4.  Efficient enrichment of hepatic cancer stem-like cells from a primary rat HCC model via a density gradient centrifugation-centered method.

Authors:  Wei-hui Liu; Xing Wang; Nan You; Kai-shan Tao; Tao Wang; Li-jun Tang; Ke-feng Dou
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

5.  A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.

Authors:  Kishore Golla; Cherukuvada Bhaskar; Farhan Ahmed; Anand K Kondapi
Journal:  J Cancer       Date:  2013-09-14       Impact factor: 4.207

6.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29

7.  Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats.

Authors:  Kishore Golla; Bhaskar Cherukuvada; Farhan Ahmed; Anand K Kondapi
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.